Journal of Ophthalmic and Optometric Sciences

Vol. 8 No. 2 (2024)

Changes in the Thickness of Different Retinal Layers Following Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema and Its Association with post Treatment Vision

Journal of Ophthalmic and Optometric Sciences, Vol. 8 No. 2 (2024), 2 April 2024 , Page 20-32
https://doi.org/10.22037/joos.v8i2.47605

Abstract

Purpose: To investigate changes in the thickness of different retinal layers following intravitreal injection of bevacizumab in patients with diabetic macular edema (DME) and its association with post treatment vision.
Patients and Methods: Bevacizumab injection was administered three times, four weeks apart. Study of retinal layer segmentation was performed manually only at the beginning of the study and at the final examination (month 6) using the SD-OCT imaging and retinal thickness was recorded in the 1, 3, and 6 mm areas of the central macula and in different quadrants.
Results: A total of 29 eyes from 29 patients were included in the study. The mean retinal thickness in the central macular area decreased from 409 ± 72 microns at the beginning of the study to 315 ± 44 microns at month six (P < 0.001). In the inner ring, the retinal thickness decreased from 410 ± 44 microns to 359 ± 25 microns (P < 0.001). These values in the outer ring were 342 ± 42 microns and 320 ± 31 microns, respectively (P < 0.001).The reduction in thickness in certain retinal layers of the inner and outer retina, along with better baseline visual acuity  (P < 0.001) were positively associated with final visual acuity.
Conclusion: Our study showed that the changes in retinal thickness after intravitreal injection of bevacizumab occurs in both the inner and outer retina, and the reduction in thickness in certain retinal layers along with better baseline visual acuity is positively associated with final visual acuity.

Keywords:
  • Thickness
  • Retina
  • Bevacizumab
  • Diabetic Macular Edema
  • Vision

How to Cite

Nikkhah, H., Valipoor, M., Ramezani, A., Karimi, S., Entezari, M., Hatami, M. M., & Shojaei, A. (2024). Changes in the Thickness of Different Retinal Layers Following Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema and Its Association with post Treatment Vision. Journal of Ophthalmic and Optometric Sciences, 8(2), 20–32. https://doi.org/10.22037/joos.v8i2.47605

References

Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346-54.

Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, Wong TY, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53(2):677-84.

Romero-Aroca P. Current status in diabetic macular edema treatments. World J Diabetes. 2013;4(5):165-9.

Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122(7):1375-94.

Nunes S, Pereira I, Santos A, Bernardes R, Cunha-Vaz J. Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. Br J Ophthalmol. 2010;94(9):1201-4.

Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(6):CD007419.

Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes. 2013;4(2):19-26.

Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-203.

Ebneter A, Wolf S, Abhishek J, Zinkernagel MS. Retinal Layer Response to Ranibizumab during Treatment of Diabetic Macular Edema: Thinner is Not Always Better. Retina. 2016;36(7):1314-23.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.

Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153-61.

Santos AR, Gomes SC, Figueira J, Nunes S, Lobo CL, Cunha-Vaz JG. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema. Ophthalmologica. 2014;231(1):16-22.

Byeon SH, Chu YK, Lee H, Lee SY, Kwon OW. Foveal ganglion cell layer damage in ischemic diabetic maculopathy: correlation of optical coherence tomographic and anatomic changes. Ophthalmology. 2009;116(10):1949-59.

  • Abstract Viewed: 80 times
  • pdf Downloaded: 80 times

Download Statastics

Current Issue